MedDataX Logo

Multi-dimensional Fragmentomic Assay for Early Detection of Pancreatic Neuroendocrine Tumors

NCT ID: NCT05847855

Last Updated: 2024-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

440 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-27

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreatic neuroendocrine tumors (pNETs) are insidious and difficult to diagnose early. Approximately 36.8% of pNET patients have lymph node metastasis\[1\], and 20% -64% of patients have liver metastasis at the time of diagnosis\[2\]. The prognosis of pNETs is closely related to tumor grade and the American Joint Committee on Cancer (AJCC) staging. Among patients with known pathological grades in the United States, well-differentiated NETs had the highest median overall survival (OS, 16.2 years), moderately differentiated NETs had the worse OS (8.3 years), and poorly differentiated or undifferentiated NETs had the worst OS (10 months)\[3\]. The 5-year overall survival rates of localized, locally advanced, and metastatic pNETs were 93%, 77%, and 27%, respectively\[4\]. Given that the prognosis of early-stage pNETs is significantly better than that of advanced pNETs, early detection of pNETs can provide a cure opportunity and significantly improve survival.

In the past few decades, the application of 68Ga-DOTANOC PET/CT, magnetic resonance imaging (MRI), computed tomography (CT), and endoscopic ultrasound (EUS) has improved the detection rate of pNETs. But their application is limited by high costs, lack of sufficient sensitivity or specificity, and radiation exposure. Therefore, there is an urgent need for accurate and less invasive approaches to use in clinical practice for the early detection of pNETs.

Recently, the study of cell-free DNA (cfDNA) has provided a noninvasive approach for the diagnosis of solid malignancies. cfDNAs represent extracellular DNA fragments released from cell apoptosis and necrosis into human body fluids like plasma, thus carrying the genetic and epigenetic information from the cell and tissue of origin\[5\]. Among them, circulating tumor DNA (ctDNA), as a part of the total cfDNA, is released into the blood by tumor cells\[6\]. cfDNA fragmentomics depends on whole genome sequencing, and its characteristics mainly include copy number variation (CNV), nucleosome footprint, fragment length and motif\[5, 7, 8\], with targets covering the entire genome level. cfDNA fragmentomics has shown excellent predictive performance in multiple studies\[5, 9-11\]. Therefore, this prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA (cfDNA) for early detection of pancreatic neuroendocrine tumors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neuroendocrine Tumor

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pancreatic neuroendocrine tumor cell-free DNA fragmentomics early detection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pNETs

Patients with pancreatic neuroendocrine tumors (pNETs).

Blood collection

Intervention Type DIAGNOSTIC_TEST

Blood collection for fragmentomic profiles of plasma cell-free DNA

Healthy

Healthy volunteers.

Blood collection

Intervention Type DIAGNOSTIC_TEST

Blood collection for fragmentomic profiles of plasma cell-free DNA

GI-NETs

Patients with gastrointestinal neuroendocrine tumors (GI-NETs) .

Blood collection

Intervention Type DIAGNOSTIC_TEST

Blood collection for fragmentomic profiles of plasma cell-free DNA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection

Blood collection for fragmentomic profiles of plasma cell-free DNA

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and above, regardless of gender;
* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor or gastrointestinal neuroendocrine tumor before surgery;
* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
* No obvious surgical contraindications;
* Able to comply with research plans, follow-up plans, and other protocol requirements;
* Voluntary participation and signed informed consent.

Exclusion Criteria

* Pathological diagnosis was not a neuroendocrine tumor;
* Currently diagnosed with other types of tumors or any cancer history;
* Diagnosed with familial syndromes;
* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;
* Recipient of blood transfusion within 30 days prior to study blood draw;
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
* Poor health condition and not suitable for blood draw;
* Any other disease/condition deemed not suitable for study enrollment by researcher.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fudan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xian-Jun Yu

President of Shanghai Pancreatic Cancer Institute

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xianjun Yu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fudan University shanghai cancer center

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xianjun Yu, MD, PhD

Role: CONTACT

Phone: 021-64175590-88503

Email: [email protected]

Shunrong Ji, MD, PhD

Role: CONTACT

Phone: 13788993956

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shunrong Ji, MD,PhD

Role: primary

Xianjun Yu

Role: backup

Shunrong Ji

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Fischer L, Bergmann F, Schimmack S, Hinz U, Priess S, Muller-Stich BP, Werner J, Hackert T, Buchler MW. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014 Oct;101(11):1405-12. doi: 10.1002/bjs.9603. Epub 2014 Aug 13.

Reference Type BACKGROUND
PMID: 25132004 (View on PubMed)

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.

Reference Type BACKGROUND
PMID: 28448665 (View on PubMed)

Zhang X, Wang Z, Tang W, Wang X, Liu R, Bao H, Chen X, Wei Y, Wu S, Bao H, Wu X, Shao Y, Fan J, Zhou J. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology. 2022 Aug;76(2):317-329. doi: 10.1002/hep.32308. Epub 2022 Jan 26.

Reference Type BACKGROUND
PMID: 34954829 (View on PubMed)

Fece de la Cruz F, Corcoran RB. Methylation in cell-free DNA for early cancer detection. Ann Oncol. 2018 Jun 1;29(6):1351-1353. doi: 10.1093/annonc/mdy134. No abstract available.

Reference Type BACKGROUND
PMID: 29668834 (View on PubMed)

Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, Chiao JY, Leal A, Noe M, White JR, Arun AS, Hruban C, Annapragada AV, Jensen SO, Orntoft MW, Madsen AH, Carvalho B, de Wit M, Carey J, Dracopoli NC, Maddala T, Fang KC, Hartman AR, Forde PM, Anagnostou V, Brahmer JR, Fijneman RJA, Nielsen HJ, Meijer GA, Andersen CL, Mellemgaard A, Bojesen SE, Scharpf RB, Velculescu VE. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021 Aug 20;12(1):5060. doi: 10.1038/s41467-021-24994-w.

Reference Type BACKGROUND
PMID: 34417454 (View on PubMed)

Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016 Jan 14;164(1-2):57-68. doi: 10.1016/j.cell.2015.11.050.

Reference Type BACKGROUND
PMID: 26771485 (View on PubMed)

Guo W, Chen X, Liu R, Liang N, Ma Q, Bao H, Xu X, Wu X, Yang S, Shao Y, Tan F, Xue Q, Gao S, He J. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. doi: 10.1016/j.ebiom.2022.104131. Epub 2022 Jun 30.

Reference Type BACKGROUND
PMID: 35780566 (View on PubMed)

Bao H, Wang Z, Ma X, Guo W, Zhang X, Tang W, Chen X, Wang X, Chen Y, Mo S, Liang N, Ma Q, Wu S, Xu X, Chang S, Wei Y, Zhang X, Bao H, Liu R, Yang S, Jiang Y, Wu X, Li Y, Zhang L, Tan F, Xue Q, Liu F, Cai S, Gao S, Peng J, Zhou J, Shao Y. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer. 2022 Jun 11;21(1):129. doi: 10.1186/s12943-022-01594-w.

Reference Type BACKGROUND
PMID: 35690859 (View on PubMed)

Ma X, Chen Y, Tang W, Bao H, Mo S, Liu R, Wu S, Bao H, Li Y, Zhang L, Wu X, Cai S, Shao Y, Liu F, Peng J. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. J Hematol Oncol. 2021 Oct 26;14(1):175. doi: 10.1186/s13045-021-01189-w.

Reference Type BACKGROUND
PMID: 34702327 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CSPAC-NEN-4

Identifier Type: -

Identifier Source: org_study_id